Summary
A post-doctoral position is available in the laboratory of Professor Jukka Westermarck at the Turku Bioscience Centre, University of Turku. The focus is on exploring the therapeutic potential of targeting the PP2A inhibitor protein CIP2A. Candidates with a strong background in structural biology and small molecule targeting are encouraged to apply.
Post-Doctoral Position in Drug Development at Turku, Finland, Finland
Designation
Post-Doctoral Researcher
Table of Details
| Detail | Information |
|---|---|
| Research Area | Cancer Drug Development |
| Location | Turku, Finland |
| Salary | 3700–4100 euros/month (based on experience) |
| Contract Period | Until April 30, 2030 |
| Trial Period | 6 months |
Eligibility/Qualification
- PhD with post-doctoral experience
- Hands-on experience in protein chemistry and interaction technologies
- First-author publication in high-quality journals related to structural biology
- Publication on phosphoproteome signaling and/or phosphatases
- Good teamwork and communication skills
Preferable Technical Competencies
- Experience with cancer cell culture methods
- Experience in small molecule targeting
- Solid understanding of CIP2A/PP2A biology
Job Description
The successful candidate will work on evaluating the therapeutic potential of targeting the CIP2A protein. The Turku Bioscience Centre is equipped with top-quality research facilities and fosters a collaborative work environment. Responsibilities include conducting experiments, publishing research findings, and working within an interdisciplinary team.
How to Apply
Submit your application via the online recruitment system including:
- A maximum 1-page application letter detailing your fit for the position
- CV
- Complete list of publications
- Copy of your PhD certificate (translated if not in Finnish or English)
- Contact details of three referees
Inquiries can be directed to Jukka Westermarck (jukwes@utu.fi) or HR Specialist Paula Luoma (paula.luoma@utu.fi).
Last Date to Apply
Applications will be assessed on a rolling basis.
For further information, please visit the Turku Bioscience Centre.
